Date: 2011-09-09
Type of information: Fundraising
Company: Aprea (Sweden)
Investors: current owners
Amount: SEK 20.4 million (€2.1 million)
Funding type: financing round
Planned used: This funding will be applied to advancing the program of Aprea’s drug candidate APR-246. The clinical study will be conducted at five Swedish sites and will together with a pre-clinical program and a 3-cyclic toxicology study in dog, provide a good basis for the design of the proof-of-concept clinical study.
Others: Aprea has secured SEK 20.4m (€2.1m) which will allow the company to complete its planned continuation of its clinical study with APR-246 in patients with hematologic malignancies. The company also announced that Torbjörn Bjerke has been elected as a new member of the board. The financing round was directed to the current owners. Furthermore, Torbjörn Bjerke, CEO of Karolinska Development, has been elected as a new member of the board of directors.
APR-246 belongs to a novel class of anticancer compounds shown to induce programmed cell death (apoptosis) through p53, a protein frequently changed in a wide range of tumors. The compound has been tested in a phase I/II clinical trial showing that it is safe at predicted therapeutic plasma levels.
Therapeutic area: Cancer - Oncology
